You have a leader in Precision Medicine
The Henry Ford Cancer Institute’s Precision Medicine program is the first and most comprehensive in Michigan to offer genomic testing and expertise of a molecular tumor board to all cancer patients.
Henry Ford Cancer Institute’s commitment to Precision Medicine was introduced in June 2016 as part of the White House’s Cancer Moonshot initiative. The HFCI Medical Director Steven Kalkanis, M.D., joined our Precision Medicine partner Syapse, at the Cancer Moonshot Summit in Washington, D.C., to announce a program to bring the most advanced cancer care to the Midwest. A huge step forward in cancer care, Precision Medicine provides advanced treatment options to patients where in many cases hope was not present.
We reaffirmed our commitment to precision medicine and to paving a path for health systems across the country to work together and share data for cutting edge cancer treatment in September 2018 at the Biden Cancer Summit. Dr. Kalkanis and Jonathan Hirsch, President of Syapse, had the honor of being among a select group to take center stage at the national summit in Washington, D.C., and present in the “Commitment to Progress” session, which reached more than 250,000 people.
Henry Ford also is among a few select health systems in the country chosen to participate in All of Us, a National Institutes of Health Precision Medicine research program.